

2nd European Conference on Cervical Cancer Screening
September 19-20, 2005
Experimentelle Virologie, Universitätsklinikum Tübingen, Germany

Program

Monday, September 19, 2005

13.00 Introduction

13.30 HPV infection and cervical neoplasia: an update

Marc Schiffman, National Institute of Health, National Cancer Institute, Rockville, USA

14.15 Other risk factors for cervical cancer

Xavier Bosch, Catalan Institute of Oncology, Barcelona, Spain

15.00 Coffee break

Results of EC-funded Follow-up studies of the "HPVCCS" trial

Presentations of the partners of the Cervical Cancer Consortium Europe (CCCE)

15.15 Structure of the "HPVCCS" trial

Thomas Iftner, University Hospital Tübingen, Section Experimental Virology, Germany

15.30 Denmark

Susanne Krüger-Kjaer, Christian Munk, Danish Cancer Society, Copenhagen, Denmark

15.50 United Kingdom

Peter Sasieni, Cancer Research UK, London, United Kingdom

16.10 Germany – Hannover/Tübingen

Karl-Ulrich Petry, Hospital Wolfsburg, Department of Obstetrics and Gynaecology, Germany

Michael Menton, Annette Stubner, University Hospital Tübingen, Department of Obstetrics and Gynaecology, Germany

16.40 Spain

Silvia de Sanjosé, Xavier Bosch, Catalan Institute of Oncology, Barcelona, Spain

17.00 Coffee break

17.30 France

Christine Clavel, Philippe Birembaut, CHU de Reims, Laboratoire Pol Bouin, France

17.50 Netherlands – Modelling/Cost Benefit Analysis

Marjolein van Ballegooijen, Erasmus University Rotterdam, Department of Public Health, Netherlands

European Guidelines and Public Awareness

18.20 European guidelines for quality assurance in cervical cancer screening

Marc Arbyn, Scientific Institute of Public Health, Brussels, Belgium

18.40 Public knowledge of HPV as risk factor for cervical cancer

Stefanie Klug, University of Mainz, IMBEI, Germany

19.00 Public awareness

Philip Davies, European Cervical Cancer Association (ECCA), Lyon, France

20.15 Reception and Dinner

Institut für Medizinische Virologie

Tuesday, September 20, 2005

Results of EC-funded Follow-up studies of the "HPVCCS" trial
Presentations of the partners of the Cervical Cancer Consortium Europe (CCCE)

9.00 Sweden

Joakim Dillner, Lund University, Department of Medical Microbiology, Malmö, Sweden

Present State of Cervical Cancer Screening in Europe

9.20 Italy

Guglielmo Ronco, CPO, Unit of Cancer Epidemiology, Piemonte, Italy

9.40 Germany - East Thuringia

Heike Hoyer, University Hospital Jena, Institute of Medical Statistics, Computer Sciences and Documentation, Germany

10.00 Netherlands

Chris Meijer, Free University Amsterdam, Department of Pathology, Netherlands

10.20 HPV infections in women from developing countries

Silvia Franceschi, IARC, Infections and Cancer Epidemiology Group, Lyon, France

10.40 Coffee break

HPV-Testing

11.10 WHO international collaborative study on the detection of HPV-DNA

Thomas Iftner, University Hospital Tübingen, Section Experimental Virology, Germany
Sonia Pagliusi, WHO, Department of Immunization, Vaccines and Biologicals, Geneva, Switzerland

11.30 Interlaboratory evaluation of PCR-based HPV detection in pathology specimens

Iver Petersen, Charité Medical School Berlin, Institute of Pathology, Germany, for the "QulP"

11.50 Meta-analysis of the diagnostic properties of HPV testing in the triage of borderline and low grade cytological lesions

Marc Arbyn, Scientific Institute of Public Health, Unit Cancer Screening, Department Epidemiology, Brussels, Belgium

Current situation of the Vaccine

12.10 Recent developments and further prospects of the vaccine

Lutz Gissmann, DKFZ, Section Infection and Cancer, Heidelberg, Germany

12.30 Efficacy and other milestones for HPV vaccine introduction

Sonia Pagliusi, WHO, Department of Immunization, Vaccines and Biologicals, Geneva, Switzerland

12.50 Closing Remarks

CCCE Lunch meeting

13.00 – 15.00 Meeting of the CCCE

- only for members of the Cervical Cancer Consortium Europe -